Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Adaptive Design Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease.

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Sep 2015 According to Forum Pharmaceuticals media release, the US FDA has placed clinical hold on all the studies investigating the effect of encenicline in Alzheimer's disease.
14 Sep 2015 Status changed from completed to suspended, as per Forum Pharmaceuticals media release.
25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com